The capacity of human neutrophils (PMN) to bind tumor necrosis factor (TNF) was rapidly lost when the cells were incubated in suspension with agents that can stimulate their migratory and secretory responses . Both physiological (poly)peptides (FMLP, C5a, CSF-GM) and pharmacologic agonists (PMN, calcium ionophore A23187) induced the loss ofTNF receptors (TNF-R) from the cell surface. Half-maximal loss in TNF-R ensued after only ti2 min with 10 -7 M FMLP at 37°C, and required only 10-9 M FMLP during a 30-min exposure . However, there were no such changes even with prolonged exposure of PMN to FMLP at 4°or 16°C. Scatchard analysis revealed loss of TNF-binding sites without change in their affinity (Kd -0.4 nM) as measured at incompletely modulating concentrations of FMLP, C5a, PMA, or A23187. The binding of antiTNF-R mAbs to PMN decreased in parallel, providing independent evidence for the loss of TNF-R from the cell surface. At the same time, soluble TNF-R appeared in the medium of stimulated PMN . This inference was based on the PMN-and FMLP-dependent generation of a nonsedimentable activity that could inhibit the binding of TNF to fresh human PMN or to mouse macrophages, and the ability of mAbs specific for human TNF-R to abolish inhibition by PMN-conditioned medium of binding of TNF to mouse macrophages. Soluble TNF-R activity was associated with a protein of Mr -28,000 by ligand blot analysis of cell-free supernatants of FMLP-treated PMN . Thus, some portion of the FMLP-induced loss of TNF-R from human PMN is due to shedding of TNF-R . Shedding was unaffectedby inhibitors of serine and thiol proteases and could not be induced with phosphatidylinositol-specific phospholipase C. Loss of TNF-R from PMN first stimulated by other agents may decrease their responsiveness to TNF. TNF-R shed by PMN may be one source of the TNF-binding proteins found in body fluids, and may blunt the actions of the cytokine on other cells.
that express CD11/CD18 (10) to release large amounts ofreactive oxygen intermediates, and promotes PMN degranulation (11) , phagocytosis (11, 12) , and antibody-dependent cytotoxicity (12) .
We set out to identify physiologic mechanisms that may counteract the potentially destructive stimulation of PMN by TNF (13, 14) . One such mechanism could involve regulation of cell surface receptors for TNF (TNF-R) . A single class of TNF-R with a Kd of 0.1-1 nM has been identified on PMN by ligand binding (15) (16) (17) . On cells other than PMN, cross-linking experiments have demonstrated association of TNF with a variety of proteins ranging from 50 to 140 kD (reviewed in reference 18) . mAbs that mimic biologic effects of TNF while inhibiting the ability of cells to bind TNF are thought to be directed against TNF-R (19) . These mAbs react with cellular proteins of -55 and 75 kD (20) , but their binding to PMN has not been documented . On some cells, the number of TNF-R can be increased by treatment with IFN-.y (21) , IL-2 (22) , or agents that elevate CAMP (23) , or decreased by exposure to IL-1 (24) , LPS (25) , activators of protein kinase C (23, 26, 27) , inhibitors of protein synthesis (28) , and drugs that depolymerize (28) or stabilize (29) microtubules. However, binding of TNF did not change after treatment of PMN with LPS (25) , cycloheximide (28) , or microtubule-disrupting agents (28) , and effects of the other regulators on TNF-R of PMN have not been described. Thus, there has been no evidence that the TNF-R of PMN are subject to regulation .
We demonstrate below that exposure of PMN to a variety of physiologic and pharmacologic stimuli results in rapid loss of TNF-R from the cell surface. Medium conditioned by stimulated PMN contained soluble molecules that bound TNF and reacted with mAbs to TNF-R. Thus, activated PMN shed TNF-R. Shedding of TNF-R by activated PMN may both blunt their responsiveness to TNF, and diminish the concentration of TNF able to act on other cells.
Materials and Methods
Cells. PMN were isolated from heparinized blood of healthy adults by centrifugation on Neutrophil Isolation Medium (Los Alamos Diagnostics, Los Alamos, NM) as described (9) . Contaminating erythrocytes were lysed with 0.2% NaCl for 90 s. PMN were washed and resuspended at 5 x 106/ml in ice-cold KrebsRinger phosphate buffer with glucose, pH 7.2-7 .4, 300 mosM (KRPG) containing 0.2% heat-inactivated FCS (HyClone Laboratories, Logan, UT). PMN were incubated in 1.5-ml polypropylene microfuge tubes (Brinkmann Instruments Co ., Westbury, NY) at 37°C with chemotactic factors, cytokines, or medium alone, while rotating end-over-end for times varying from 1 to 90 min. For incubations of <10 min, the cells were prewarmed for 10 min at 37°C before addition of the stimulus . After incubation, the cells were washed with cold KRPG, resuspended in binding buffer, and tested for TNF-R as described below.
Peritoneal exudates were elicited in CD1 mice (Charles River Breeding Laboratories, Wilmington, MA) with thioglycolate broth (Difco Laboratories, Detroit, MI) and the cells harvested as described (25) . Monolayers of adherent macrophages were obtained by plating 1 x 106 cells/well in 16-mm-diameter wells in plastic trays (Costar Data Packaging, Cambridge, MA) in a-modified MEM (ceMEM ; KC Biological, Lenexa, KS) with 10% FCS. Macrophages were maintained at 37°C in 5% CO 2/95% air for 1-4 d before experiments.
Stimuli and Other Reagents. All cytokines were pure, recombinant proteins of human origin . TNF (5 .6 x 10' U/mg) produced in Escherichia coli was a gift of Genentech (South San Francisco, CA). IFN-y (1 x 10' U/ml) and transforming growth factor-(31 (TGF-01, 50 hg/ml) were gifts of Amgen (Thousand Oaks, CA). CSF for granulocyte/macrophage (CSF-GM, 1.4 x 10' U/ml ; from Chinese hamster ovary cells) was from Genetics Institute (Cambridge, MA). IL1-/3 was a gift of Dr. C. Dinarello (Tufts New England Medical Center, Boston, MA). Pure, recombinant human C5a was provided by Dr. Henry Showell, Pfizer Inc. (Groton, CT).
FMLP, PMA, and the calcium ionophore A23187 were from Sigma Chemical Co. (St. Louis, MO). Stock solutions of FMLP (10 -' M) and A23187 (10 -2 M) in DMSO were stored at -70°C. Protease inhibitors were from Sigma Chemical Co. Phosphatidylinositol-specific phospholipase C from Bacillus thuringiensis was from Dr. M.G. Low (Columbia University College of Physicians and 600
Shedding of Tumor Necrosis Factor Receptors by Neutrophils Surgeons, New York, NY), and was a gift of Dr. A . LeBivic, Cornell University Medical College. Antibodies. Purified mouse IgG1 mAbs Htr-5, Htr-9, and Utr-1 specific for human TNF-R, prepared as described (20) , were the gift of Dr. Manfred Brockhaus, F. Hoffman-La Roche AG, Basel, Switzerland. Purified mouse IgG2a mAbs 1134 (anti-CD18) and W6/32 (anti-HLAA, $ C) were gifts of Dr. S. Wright, The Rockefeller University, New York, NY Purified mouse IgM mAb BH2C6 anti-p157 (not CD11) (30) was the gift of Dr. J. Michl, SUNY, Brooklyn, NY Affinity purified F(ab')2 fragments of goat IgG anti-mouse IgG were from Cappel Laboratories (Organon Teknika Corp ., West Chester, PA).
Iodination of Cytokines andAntibodies. TNF and affinity-purified F(ab')2 fragments of anti-mouse IgG were radiolabeled with 1251 according to the method of Aggarwal et al . (21) using Iodogencoated tubes and 0.5-1 mCi of Na 1 a'I (100 mCi/ml; Radiochemical Center, Amersham). As before (25, 28, 29) , 1251TNFa had a specific activity of 200-400 Ci/mmol monomer, migrated as a single band of 17 kD on 11% polyacrylamide gels, and retained fully its ability to enhance H202 releasing capacity of resident mouse peritoneal macrophages . Radiolabeling of rhuIFN-y was performed as described (31) .
Binding Assays. Replicate samples of 1 x 10 6 PMN in 0.3 ml of KRPG containing 5% FCS (binding buffer) were incubated with the indicated concentrations of 1251 TNF (0.1-2 nM) or 1251-IFN-y (2 nM) in the presence or absence of a 100-fold molar excess of unlabeled ligand to determine nonspecific binding. After 3 h at 4°C (sufficient to reach equilibrium), the cells were washed three times with 0.9% NaCl by centrifugation (180 g, 10 min, 4°C) and solubilized with 30 p.l of 1 N NaOH . The lysates were transferred into new tubes for gamma counting (Packard Instrument Co., Downers Grove, IL). Nonspecific binding was <15% of total binding and was subtracted . Protein concentration of the solubilized samples was determined by the assay of Lowry et al . (32) . Results are expressed as specific cpm bound per 100 lAg protein.
Binding of 12'ITNF-a to monolayers of adherent macrophages was measured as described (25, 28, 29) .
For binding of mAbs, PMN (1 x 106 in 100 pl of KRPG with 10% FCS) were incubated with saturating amounts of mAbs (10-20 pg/ml) for 1 h at 4°C, washed twice in KRPG-10% FCS, and reacted for an additional 30 min at 4°C with 1251-F(ab') 2 antimouse IgG (500,000 cpm) . After three washes in saline (180 g, 4°C, 10 min), bound cpm and protein were measured as above. Background binding was determined by omitting the primary antibody and was subtracted . It varied from 2 to 5% of total binding for anti-HLA and anti-CD18 mAbs, to -30% for mAbs antiTNF-R.
Assayfor Soluble TNF-R. TNF-R were detected in the conditioned medium of stimulated PMN by competition with 1251-TNF for its binding to fresh PMN or macrophages . PMN (1 .0-1 .2 x 10 8/ml) were incubated in KRPG-I% FCS for 10 min at 37°C with FMLP (10 -1 M) or medium alone. The supernatants were harvested by centrifugation (180 g, 10 min, 4°C), centrifuged again (12,000 g, 5 min, 4°C), and incubated with 2 nM 1251-TNF in the presence or absence of 200 nM unlabeled TNF and/or a mixture of the anti-human TNF-R mAbs Htr-5, Htr-9, and Utr-1 (5 hg/ml each). After 30 min at 4°C, the mixtures were transferred to wells containing monolayers of macrophages or 1 x 10 6 fresh PMN, and binding was allowed to proceed for 3 h at 4°C as described above. As a control, 10 -6 M FMLP was added to supernatants from buffer-treated cells during the binding assay.
Gel Electrophoresis and Ligand Blot Analysis. Cell-free supernatants of PMN treated with buffer alone or stimulated with FMLP were resolved by electrophoresis in 5-15% polyacrylamide gradient gels according to the procedure ofLaemmli (33) under nonreducing conditions . The proteins were then transferred to nitrocellulose membranes (Schleicher & Schnell Inc., Keene, NH) at 100 V for 1 h at room temperature, using the buffer systems described by Burnette (34) . The nitrocellulose sheets were blocked with 1% nonfat dry milk in 50 mM Tris-HCI pH 7.4,140 mM NaCl, 5 mM EDTA and 1 mM sodium azide for 2 h at room temperature before addition of 1251TNF (0.5 nM) in the presence or absence of 100 nM unlabeled TNF. After 16 h at 4°C, the membranes were washed four times with PBS at room temperature, dried, and autoradiographed . Measurement of LPS. The level ofcontaminatingLPS in all media and reagents was monitored by a chromogenic limulus amebocyte lysate test (Whittaker Bioproducts, Inc ., Walkerville, MD) with a sensitivity of 10 pg/ml.
Results
E$ects ofPMNActivators on Expression of TNFR . Exposure of PMN for 45 min at 37°C to FMLP (10 -e to 10-7 M), PMA (100 ng/ml), or calcium ionophore A23187 (10 -5 M) resulted in almost complete inhibition of the subsequent binding of 125 1-TNF at 4°C ( Table 1) . Exposure of PMN to C5a (10 -1 M) or CSF-GM (100 ng/ml) also suppressed their subsequent binding of TNF. However, in contrast to the effect Results are means ± SD from the number of independent experiments indicated in parentheses .
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Porteu and Nathan observed with FMLP, PMA, or A23187, the decrease in 1251-TNF binding induced by C5a or CSF-GM was never complete; 30-50% specific binding remained even when the incubation time was prolonged to 2 h at 37°C (not shown) .
In contrast, IFN-y, ILla, and TGF-(31 (each 100 ng/ml) had little or no effect on TNF-R expression (Table 1) . A 45-min exposure to high concentrations of LPS (0.1-1 hg/ml) reduced 125 1-TNF binding only slightly (20-30%), and a 10-min exposure to LPS had no detectable effect ( Table 1 ). The measured LPS content of all reagents at the concentrations used was <10 pg/ml. Thus, downregulation of TNF-R induced by other agents could not be attributed to contamination by LPS.
Kinetic Studies of TNF-R Modulation . The decrease in binding of 125 ITNF induced by FMLP was extremely rapid, 50% reduction being reached after N3 min treatment with 10-8M FMLP (Fig. 1) . Complete loss of 125 1TNF binding required 6-10 min exposure to 10-1 M FMLP or 12-15 min exposure to 10 -8 M FMLP (Fig. 1) . Likewise, binding of 125 ITNF to PMN was decreased to 0-5% that of control cells by 10 min after addition of PMA or A23187, and 30-70% binding capacity of the cells was lost upon a 10-min incubation with C5a and CSF-GM ( Table 1) .
The decrease in TNF binding induced by FMLP was relatively long lasting . After PMN were exposed to FMLP for 15 min and washed, their capacity to bind TNF recovered only partially during a subsequent 2-h incubation at 37°C (Table 2) . Recovery studies were not carried out to longer times because prolonged incubation was associated with a fall in TNF-R on control PMN (data not shown) .
Temperature Dependence. In contrast to the results obtained at 37°C, pre-exposure of PMN for 30 min at 4°C to FMLP, C5a, CSF-GM, A23187, or PMA, or addition of these factors during the binding assay, did not affect TNF binding. Neither FMLP nor C5a induced a decrease in TNF binding when (Table 3) or a surface antigen of 157 kD (30) (not shown) . Under the same conditions, cell surface expression of CD18 increased two-to threefold (Table 3) . Thus, the decrease in TNF-R induced by FMLP was relatively selective.
Decreased Binding of TNF Resultsfrom Loss of TNF-R . The rapid decrease of TNF binding induced by PMN activators could be due to a conformational change of the receptor, resulting in decreased affinity for its ligand, or to a loss of receptors from the cell surface. To distinguish between these possibilities, buffer-or FMLRtreated PMN were reacted with increasing concentrations of 125 1-TNF and the specific binding values were analyzed according to Scatchard (35) . (Table 4) .
Independent evidence that TNF-R were lost from the cell surface of activated PMN was provided by reacting FMLPand buffer-treated PMN with mAbs against TNF-R, followed by 125 1-F(ab')2 anti-mouse IgG. As shown in Table 5 To test for a role of endocytosis, PMN were pretreated with the microfilament-disrupting agent cytochalasin B (10 Ag/ml) for 30 min at 37°C before adding FMLP. As shown in Fig.  3 , cytochalasin B did not prevent the decrease in TNF binding induced by FMLP. On the contrary, cytochalasin B synergized with FMLP to augment loss of TNF-R.
To examine the possibility that activated PMN might shed TNF-R, we tested cell-free supernatants of stimulated PMN for soluble TNF-R in a radioreceptor assay. PMN were incubated for 10 min at 37°C with FMLP or buffer alone. The cell-free incubation media were collected and their ability to compete with not respond to FMLP. As a control, FMLP was added to supernatants of buffer-treated PMN during the binding assay at 4°C. Fig. 4 shows that supernatants from FMLP-stimulated PMN inhibited 1251 TNF binding to fresh PMN and mouse macrophages, while supernatants from buffer-treated neutrophils had no effect . To determine whether the moieties that blocked 1251-TNF binding were related to TNF-R, we used antiTNF-R mAbs Htr-5, Htr-9, and Utr-1, and chose murine macrophages as indicator cells in the competition assay. The specificity of these mAbs for the human as opposed to the mouse TNF-R was shown by their ability to block completely the binding of 1251 TNF to human PMN while inhibiting binding to mouse macrophages by only 10-20% (Fig. 5 A) . Preincubation of cell-free supernatants from FMLP-stimulated PMN with a mixture of these mAbs (5 14g/ml each) totally reversed their inhibitory effect on 125 1-TNF binding to mouse macrophages (Fig. 5 B) .
To test if TNF-R released from stimulated PMN were soluble rather than associated with membrane fragments, supernatants of PMN treated with FMLP were ultracentrifuged (100,000 g, 1 h, 4°C) or passed through a 0.22-jAm filter (Millipore Corp., Danvers, MA) . Neither procedure diminished the ability of the conditioned media to block 125 1-TNF binding to cells (data not shown) . Microscopic examination ofboth FMLP-and buffer-treated PMN revealed monodisperse cells with >95% viability by trypan blue exclusion, indicating that the generation of soluble TNF-R from PMN was not a consequence of cell death .
Characterization of Soluble TNF-R by Ligand Blotting. Supernatants from buffer-or FMLP-treated PMN were subjected to SDS-PAGE, transferred to nitrocellulose membranes and probed with 1251 TNF. Two 1251 TNF binding proteins were identified in the supernatants ofFMLP-stimulated PMN (Fig.  6 A) : a major species of ti95 kD and a N28-kD molecule which appeared as a diffuse, less intense band. In the presence of a 200-fold excess of unlabeled TNF, binding of 1251_ TNF to the higher-Mr band was unaffected . The identity of the ti95-kD protein that binds TNF nonspecifically is unknown. In contrast, unlabeled TNF completely eliminated binding of 1251 TNF to the N28-kD protein (Fig. 6 B) . However, no 1251 TNF-binding proteins were detected in ligand blots of supernatants from PMN that were not exposed to FMLP (Fig. 6 C) , even when autoradiography was prolonged from 3 d (Fig . 6 ) to 3 wk (not shown) . Thus, FMLP triggered PMN to release a soluble N28-kD protein that bound TNF specifically. Effect of Protease Inhibitors. To test if proteolytic cleavage were responsible for shedding of TNF-R, PMN were stimulated with FMLP in the presence or absence of inhibitors of serine or thiol proteases . The decrease in 125 1-TNF binding to PMN induced by FMLP could not be prevented by addition of diisopropylfluorophosphate (DFP), trypsin inhibitor, PMSF, leupeptin, aprotinin, or pepstatin (Table 6 ).
Discussion
Downregulation of cell surface receptors is one means by which cells control their responses to agonists . At least two mechanisms serve to decrease the number of TNF-R on various cells : internalization induced by homologous (27, 37, 38) or heterologous ligands (25, 26) , and reduced rates of TNF-R synthesis and/or translocation to the plasma membrane (28) . Neither of these mechanisms has been detected in PMN (25, 28) . In contrast, PMN appear to use a third mechanism, shedding, to decrease rapidly the number of TNF-R on their surface . Along with FcRIII (CD16) (39) and the MEL 14 selectin (40), TNF-R is the third plasma membrane receptor that PMN are known to shed upon activation .
Activators of PMN function that induced a decrease in TNF-R included physiologic peptides (FMLP) and polypeptides (C5a, CSF-GM) of bacterial or human origin, and pharmacologic agents that activate protein kinase C (PMA, A23187) . The decrease in TNF-R expression induced by all these agents was rapid, and required cell metabolism, judging by its temperature dependence. Shedding seemed to account for at least part of the decreased expression of TNF-R, in Factor Receptors by Neutrophils that a loss of TNF-R binding sites (as estimated by Scatchard analysis ofTNF binding, and by binding of anti-TNF-R mAbs) was coincident with the appearance in the medium of soluble molecules capable of binding both TNF and anti-TNF-R mAbs. However, we could not quantitate soluble TNF-R, and thus could not establish whether shedding accounted completely for the disappearance of TNF-R from the PMN surface. It is possible that only some plasma membrane TNF-R were shed; others may have been lost by internalization or degradation . By whatever mechanism(s), the loss of TNF binding sites often appeared to reach 100%.
Shedding of many plasma membrane receptors from cells other than PMN has been described. Examples are the antigenbinding molecules, MHC class I (41) and class 11 (42) ; the adhesion molecule CD8 (43); and receptors for IgE (44), IIr2 (45) , and insulin (46) . The biochemical processes involved are not well understood. In some instances, release of plasma membrane vesicles is involved (41, 42) . This probably did not account for shedding of TNF-R from PMN, since the inhibitor of TNF binding in supernatants of activated PMN was not sedimented by ultracentrifugation. Perhaps selective proteolytic cleavage (45) releases TNF-R, while preserving its ability to bind both TNF and antiTNF-R mAbs. If so, then the role of PMN activators may be to promote exocytosis of lysosomal proteases . However, we could not prevent FMLP-induced loss of TNF-R with DFP, PMSF, soybean trypsin inhibitor, leupeptin, and pepstatin. This militates against a role for serine or thiol proteases, but leaves open the possibility that a protease insensitive to these inhibitors may be involved . Proteins anchored to membranes via glycosylphosphatidylinositol can be shed after cleavage by phospholipases (47) . Such a mechanism may underlie the FMLRinduced shedding of FcRIII (39). However, we were able to affect the expression ofTNF-R on PMN with phosphatidylinositolspecific phospholipase C (data not shown) . We are only likely to understand the mechanism of shedding of PMN TNF-R after both its membrane and soluble forms have been purified. Soluble TNF-binding proteins of 27 to 50 kD have been isolated from the urine ofnormal (48) and febrile individuals (49) and the sera of patients undergoing hemodialysis (50) . At least two of these proteins share immunological reactivity with TNF-R of myeloid and epithelial cell lines (48) . The findings presented here raise the possibility that some TNFbinding proteins in body fluids may consist ofor derive from TNF-R shed by PMN . The apparent 28,000 Mr of TNF-R shed by PMN is consistent with this possibility.
At first glance, the observations made here in vitro might appear to preclude the possibility that PMN can respond to TNF in vivo, where multiple stimuli, including C5a and formylated peptides of bacterial . (51) and/or mitochondrial (52) origin, are likely to be present during infection or tissue injury. However, consideration ofthis issue must take into account the rapidity with which the binding of TNF to its receptor commits PMN to subsequent responses (Nathan, C., unpublished observations), the retention of a substantial number of TNF-R after exposure to C5a, and the sequence in which PMN may encounter various stimuli as they move from the circulation into tissues. Another key variable is whether the PMN are in suspension, as in the present study, or have made contact with biological surfaces before being stimulated (Porteu, F., and C. Nathan, preliminary observations) .
TNF is a major mediator of host responses to endotoxin (4) . Responses ofPMN to TNF may contribute to the pathogenesis of septic shock and respiratory distress syndromes. Downregulation of TNF-R on PMN that first encounter another agonist in the circulation may represent an important mechanism for protecting the host against deleterious effects of TNF. At the same time, soluble TNF-R released by activated PMN might serve an immunoregulatory role by interfering with the binding of TNF to other cells . Administration of soluble, recombinant, human TNF-R might protect people against the consequences of excessive production of TNF, without the antitherapeutic immune response expected to follow the administration ofmAbs against TNF or TNF-R.
It is also possible that a soluble form ofTNF-R has cytokinelike actions of its own, just as soluble FcERII mimics 1172 (53) . If so, a cell surface receptor for soluble TNF-R could be the 26-kD form of TNF present on the plasma membranes of monocytes (54) and activated T cells (55) . According to this view, not only could mononuclear cells signal PMN (9), but PMN could signal mononuclear cells in the regulation of inflammatory responses.
